Cheaper or pricier? trial pits two eye drugs against each other for diabetes vision loss
NCT ID NCT06850571
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares two drugs, aflibercept and bevacizumab, given as eye injections to treat diabetic maculopathy, a complication of diabetes that can blur vision. About 102 Iraqi patients with type 2 diabetes will receive monthly injections for three months. Researchers will measure vision changes, eye thickness, side effects, and cost to see which drug offers better value.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aflibercept and bevacizumab (anti-VEGF drugs injected into the eye)
- What this could lead to
- If successful, this could show which drug works better and is more cost-effective for treating diabetic maculopathy, helping guide treatment choices.
- What could go wrong
- This is a small, single-country trial with only 102 participants, so results may not apply broadly. Both drugs have known risks like eye infection or inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baghdad Medical City Complex
RECRUITINGBaghdad, 10001, Iraq
More trials for these conditions
Other studies related to the condition(s) this trial covers.